Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Intel: Heart Attack Therapy Firms Seek Unobstructed Path For MVO Solutions

Executive Summary

When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.

You may also be interested in...



FDA Approves TherOx’s SuperSaturated Oxygen Heart Attack Therapy

Clinical trials have shown that SuperSaturated Oxygen Therapy (SSO2 Therapy) reduces the size of myocardial infarcts in the regions of the heart-muscle perfused by the patient’s left anterior descending coronary artery immediately following stenting.

TCT 2018: New ABSORB Trial Data Fails To Impress

Abbott's defunct Absorb BVS stent's efficacy is noninferior to that of the Xience metallic everolimus-eluting stent, new data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego show. But the risk of thrombotic events was still higher with Absorb. This prompted a discussion among panelists whether bioresorbable stents should still be investigated, given the availability of newer-generation drug-eluting stents, which have shown to be safer.

Medicare Bonus Payments: CMS Plans To End Three, But Considers Seven New-Tech Add-On Payments For FY 2019

While the US Medicare agency is proposing to end hospital inpatient new-technology add-on payments for Edwards Lifesciences’ and LivaNova’s minimally surgical valves, and for WL Gore's endoprosthesis aneurysm device, it is evaluating possible bonus payments for 7 more devices beginning Oct. 1.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel